Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:16 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Proof-of-Concept Study Investigating the Safety and Efficacy of ZT-031 on Hip Fracture Healing in Men and Postmenopausal Women
NCT00787358 · Zelos Therapeutics · PHASE2 · withdrawn · last registry update 2009-06-04 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Change in company direction” | – | Registry record, Zelos Therapeutics |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PTH1R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2009-09-30Results posted on the registry: Eli Lilly and Company, Teriparatide + Placebo (NCT00433160)
- 2009-08-26Results posted on the registry: Eli Lilly and Company, Teriparatide + Salmon Calcitonin (NCT00414973)
- 2009-06-24Results posted on the registry: Eli Lilly and Company, teriparatide (NCT00577863)
- 2009-02-13Results posted on the registry: Eli Lilly and Company, Teriparatide + Alendronate Sodium (NCT00051558)
- 2008-06-13Phase 3 first posted: Columbia University, Teriparatide (PTH 1-34) (NCT00697463)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision